Piper Sandler Upgrades Intra-Cellular Therapies to Overweight, Raises Price Target to $92
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has upgraded Intra-Cellular Therapies (NASDAQ:ITCI) from Neutral to Overweight and increased the price target from $68 to $92.
September 06, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has upgraded Intra-Cellular Therapies to Overweight and raised the price target to $92, indicating a positive outlook on the stock.
The upgrade from Neutral to Overweight by Piper Sandler suggests increased confidence in ITCI's future performance. The raised price target from $68 to $92 indicates a significant expected upside, likely leading to positive short-term stock movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100